Sign in
RYTM Stock Price, Chart, Stats & News
Rhythm Pharmaceuticals, Inc.
Save
7.43B
Market cap
–
Current P/E
–
Forward P/E
RYTM chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 89.73% |
Operating margin | -101.19% |
Pretax margin | -103.31% |
Net margin | -103.57% |
Effective tax rate | -0.25% |
ROA | -40.84% |
ROE | -179.05% |
D/E | 1.77x |
Interest coverage ratio | -9.33x |
RYTM valuation
P/E | – |
P/S | 27.28x |
P/B | 36.46x |
P/CF | -43.83x |
P/FCF | -44.39x |
P/OCF | -43.83x |
PEG | 79.98x |
EV multiple | -28.63x |
About
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes.
Similar securities
Based on sector and market capitalization
Report issue